Our Bayesian joint modeling approach effectively addresses terminal intercurrent events in both the design and analysis phases of clinical trials. By explicitly accounting for event-related truncation of longitudinal follow-up, it improves the precision and reliability of treatment effect estimation when outcome measurement is incomplete.
Teng et al. (Sat,) studied this question.